Clinical trials: HIV Reservoir
HIV Infections
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor.
- Trial name
- NCT00051831
- Testing
- Emtricitabine, Enfuvirtide, Ritonavir
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.
- Trial name
- REDUC (NCT02092116)
- Testing
- Romidepsin, Vacc-4x, rhuGM-CSF
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Bionor Immuno AS
HIV-1
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection
To evaluate the safety of autologous CAR-T-cell therapy in individuals lived with HIV-1 infection, CAR T cells are infused after ex vivo expansion and transduction with lentiviral vectors encoding a broadly neutralizing HIV-1…
- Trial name
- TCTIWHI (NCT04863066)
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Beijing 302 Hospital
Chronic HIV-1 Infection
Towards HIV Functional Cure
During the ERAMUNE-01 and -02 studies, the HIV-DNA quantification in the PBMCs (Peripheral Blood Mononuclear Cells) showed showed that some patients had a very low or undetectable reservoir.
- Trial name
- ULTRASTOP (NCT01876862)
- Testing
- Antiretroviral treatment interruption
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- Objectif Recherche Vaccins SIDA
HIV Infections
Efficacy of Lauric Acid, a Dietary Fatty Acid, in Modifying the Latent Reservoir of HIV
Dietary lauric acid supplementation could have a significant impact on the HIV reservoir in antiretroviral-treated patients by inducing HIV viral transcription in latently infected cells and preserving the HIV-specific immune…
- Trial name
- FATHIV (NCT05687565)
- Testing
- Experimental group 1 lauric acid, Experimental group 2 lauric acid
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Human Immunodeficiency Virus
Tissue Drug Levels of HIV Medications
The aim of this study is to find out why HIV continues to make copies in people taking HIV drugs. The investigators want to know if the medications most people use to treat HIV get into the lymphatic tissue where HIV persists.
- Trial name
- NCT01490346
- Testing
- Initiation of anti-retroviral therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
HIV/AIDS
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating latent HIV-1 reservoir, providing potential strategies for AIDS functional cure.
- Trial name
- NCT03980665
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV
HIV Sequencing After Treatment Interruption to Identify the Clinically Relevant Anatomical Reservoir
The main goal of this study is to identify and characterise the anatomical component of the replication competent HIV-1 (Human Immunodeficiency Virus-1) reservoir.
- Trial name
- HIV-STAR (NCT02641756)
- Testing
- treatment interruption after in depth sampling under CART
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- University Hospital, Ghent
HIV Infections
Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)
This is a 24 week placebo controlled, double-blind, 2-arm study of ADAPTAVIR, Monomeric Dala1-peptide T-amide (mDAPTA) compared to placebo, in HIV infected individuals with suppressed plasma viral loads < 200 copies/ml by highly…
- Trial name
- NCT00951743
- Testing
- Adaptavir (monomeric DAPTA)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rapid Laboratories Inc.
HIV, Acute HIV Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
- Trial name
- PHI-05 (NCT02384395)
- Testing
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
AIDS, HIV
Perturbing of HIV Reservoir With Immune Stimulation
The purpose of this study is to determine the impact of Pneumococcus and Influenza vaccines on the HIV transcriptional activity in individuals who are virologically suppressed for at least 48 weeks on similar ART.
- Trial name
- NCT02707692
- Testing
- Fluarix, Pneumovax
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Diego
HIV
Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)
The AELIX-002 study aims to evaluate the safety and the immunogenicity of an heterologous prime-boost regimen with DNA.HTI, MVA.HTI and ChAdOx1.HTI in early diagnosed and treated HIV-1 positive individuals, males and…
- Trial name
- NCT03204617
- Testing
- DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM), At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Aelix Therapeutics
Human Immunodeficiency Virus, Growth Hormone Treatment
Impact of Recombinant Human Growth Hormone on HIV Persistence
Antiretroviral therapy (ART) has improved the health of more than 18 million people infected with HIV by controlling viral replication, AIDS and non-AIDS events, and by reducing the risk of transmission.
- Trial name
- NCT03091374
- Testing
- Somatotropin (Human)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population.
- Trial name
- ViDyMoCo (NCT02836782)
- Testing
- Blood sample withdrawal
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Catholic University of the Sacred Heart
HIV Infections
Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs
For a few years, there has been a keen interest of clinicians and patients for "lighter" antiretroviral strategies based on two- or even single drug regimens rather than the canonical triple therapy, both as initial and…
- Trial name
- IDOLTIB (NCT04034862)
- Testing
- Treatment simplification (dolutegravir lamivudine)
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- University of Liege
HIV, Stable ART
Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People
To assess the safety and tolerability of ALT-803, as well as, the potential efficacy of ALT-803 in HIV
- Trial name
- ALT-803 (NCT02191098)
- Testing
- ALT-803
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Minnesota
Acute HIV Infection
Effects of Intensive cART During Acute/Early HIV Infection
This trial will investigate the efficacy and safety of intensified antiretroviral treatment that includes raltegravir and maraviroc during the early stages of HIV infection.
- Trial name
- NCT01154673
- Testing
- raltegravir, maraviroc, emtricitabine 200mg /tenofovir 300mg
- Where
- 2 sites in Canada
- Volunteers
- 32 people
- Sponsor
- University of Toronto
HIV Infection
HIV Reservoir Reduction With Interleukin-2
The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV…
- Trial name
- IL2 (NCT03308786)
- Testing
- Recombinant Interleukin-2
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Western Reserve University
Acute HIV Infection
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: Administration of…
- Trial name
- NCT05719441
- Testing
- VRC07-523LS, PGT121.414.LS, ART
- Where
- 12 sites in United States, Brazil and 1 more
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV - Human Immunodeficiency Virus
Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment
Contemporary ART fails to eradicate the HIV-1 virus from PWH, resulting in a rebound in viremia within days to weeks after cessation of ART.
- Trial name
- NCT07903441
- Testing
- Multiple therapeutic interventions
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo